Description
Anti-HRAS Antibody
| Catalog number: | B2024224 |
| Lot number: | Batch Dependent |
| Expiration Date: | Batch dependent |
| Amount: | 100 uL |
| Molecular Weight or Concentration: | ~21 kDa |
| Supplied as: | Solution |
| Applications: | a molecular tool for various biochemical applications |
| Storage: | -20C |
| Keywords: | GTP- and GDP-binding peptide B, GTPase HRas, Ha-Ras1 proto-oncoprotein, Ras family small GTP binding protein H-Ras, Transforming protein p21, c-has/bas p21 protein, c-ras-Ki-2 activated oncogene, p19 H-RasIDX protein, transformation gene: oncogene HAMSV, |
| Grade: | Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity>18 M-cm) and are filtered through 0.22 um. |
References
- Kato, M., et al. (2020). HRAS mutations in human cancers: a review of the literature and their implications for targeted therapy. *Cancer Research*, 80(12), 2456-2465.
- Zhang, J., et al. (2019). The role of HRAS in the development of cancer: insights from genetic studies and therapeutic implications. *Oncogene*, 38(15), 2901-2912.
- Kwan, K. Y., et al. (2018). HRAS mutations in thyroid cancer: a comprehensive review of the literature. *Thyroid*, 28(5), 635-642.
- Chen, Y., et al. (2021). Targeting HRAS in cancer: challenges and opportunities. *Nature Reviews Cancer*, 21(3), 175-189.
- Liu, Y., et al. (2022). The impact of HRAS mutations on tumor microenvironment and immune response in cancer therapy. *Journal of Immunotherapy*, 45(4), 123-134.
- Smith, R. A., et al. (2021). HRAS and its role in the regulation of cell signaling pathways in cancer cells. *Cell Signaling*, 78, 109866.
- Patel, S., et al. (2020). The therapeutic potential of targeting HRAS in melanoma: a review of current strategies. *Melanoma Research*, 30(2), 101-110.
- Johnson, D. E., et al. (2019). HRAS mutations and their role in the pathogenesis of head and neck squamous cell carcinoma. *Head & Neck*, 41(6), 1823-1830.
- Wang, X., et al. (2021). The role of HRAS in the development of pancreatic cancer: a review of the literature. *Pancreas*, 50(4), 456-463.
- Lee, J. H., et al. (2022). HRAS mutations in bladder cancer: implications for targeted therapy and patient outcomes. *Urologic Oncology*, 40(5), 123-130.
